Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (tnf-alpha) and is used to treat autoimmune diseases. infliximab was approved by the u.s. food and drug administration (fda) for the treatment of crohn s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. it is used off-label outside its fda approval for beh
et s disease and other conditions. infliximab is administered by intravenous infusion, typically at six- to eight-week intervals.